After months of blaming China and the World Health Organization for the scope and severity of the COVID-19 pandemic, President Donald Trump lashed out at both again Friday with a trio of policies that could...

Cotellic/Tecentriq combo misses in melanoma Exelixis Inc. (NASDAQ:EXEL) revealed in a Thursday SEC filing that Cotellic cobimetinib plus Tecentriq atezolizumab from partner Genentech Inc. missed the primary endpoint of improving progression-free survival vs. Keytruda pembrolizumab...

Castle Creek Pharmaceuticals LLC (Parsippany, N.J.) discontinued the Phase II DELIVERS trial evaluating topical 1% diacerein (AC-203, CCP-020) to treat epidermolysis bullosa simplex (EBS). According to ClinicalTrials.gov, an IDMC said the trial will not meet...

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...

Vernalis plc (LSE:VER) said FDA issued a complete response letter to an NDA for CCP-08 to treat cough and cold. The letter follows a CRL issued in April for its other cough and cold candidate...

Vernalis plc (LSE:VER) lost 2p (11%) to 17p Monday after it said FDA issued a complete response letter to an NDA for CCP-08 to treat cough and cold. The letter follows a CRL issued in...

Castle Creek Pharmaceuticals LLC (Parsippany, N.J.) began the Phase II/III DELIVERS trial to evaluate topical 1% diacerein (AC-203, CCP-020) in about 80 patients ages ≥4 with epidermolysis bullosa simplex. The double-blind, international trial will test...

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...

The top three market cap tiers continued to outperform smaller caps in 2Q17, led by companies valued between $1 billion and $9.9 billion. Companies valued below $1 billion failed to carry over their momentum from...

FDA issued a complete response letter to an NDA from Vernalis for CCP-07 to treat cough and cold. The company said the CRL did not identify issues with the candidate's formulation or pharmacokinetic profile, but...